Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283957 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
A Phase 2 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT02283957 is a Phase 2 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 119 participants.
The verdict
NCT02283957, a Phase 2 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
Study 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton's neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.
Interventions
- OTHER Placebo
- DRUG CNTX-4975
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283957
The ClinicalTrials.gov registry entry for NCT02283957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02283957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02283957 about?
NCT02283957 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)". Study 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton's neuroma. The injection of study medication will be administere...
What is the current status of trial NCT02283957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2014-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02283957?
The interventions under investigation include: Placebo (OTHER), CNTX-4975 (DRUG).
Who is sponsoring clinical trial NCT02283957?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.